Yinjia (Shanghai) Biomedical Technology

Yinjia (Shanghai) Biomedical Technology Co., Ltd. is a protein technology research and development company established in November 2020. The company's founder is Dr. Wu Yifei, who serves as Chairman and CEO.

Yinjia focuses on the application of proteins in biomedicine and other life science fields. It has developed a protein R&D platform that utilizes computer simulation, artificial intelligence, and Cell-Free Protein Synthesis (CFPS) technologies. The company produces high-quality protein-based biomaterials and reagents for applications such as early cancer diagnosis, new drug development, and personalized medication guidance. Its product portfolio includes nearly 200 high-end protein raw materials and quality control testing reagents for therapeutic biologics. These products cover frontier fields like cell and gene therapy (CGT), mRNA and circRNA vaccines, molecular diagnostics, and new anti-tumor drugs. Specific offerings mentioned include Vaccinia Capping Enzyme, 2'-O-methyltransferase, and T7 RNA Polymerase V2, which are produced using E. coli expression systems.

The company operates on a B2B model, providing its products to pharmaceutical companies, innovative drug developers, and diagnostic companies to support their research and development efforts. Yinjia has established laboratories and GMP pilot production platforms in Shanghai, Suzhou, and Beijing. Strategic partnerships are a key part of its growth strategy. In 2021, Yinjia signed a deal with US biotech firm IsoPlexis to advance a proteomics data analysis platform for monitoring therapeutic effects on tumor patients. In 2023, it partnered with Porton Advanced Solutions to develop core protein raw materials and quality control reagents for the CGT sector.

Yinjia has successfully completed multiple funding rounds. It secured tens of millions of yuan in a seed round in January 2021 from investors including CDH Venture and Growth Capital Fund. This was followed by a Pre-A round in July 2021, led by Gaorong Capital, which also raised tens of millions of yuan. In December 2022, the company completed a Series A round of over CNY 100 million (approximately $14M), led by CMB International. Other notable investors across its funding stages include InnoPinnacle and Shanghai Furong Investment. These funds have been allocated towards talent recruitment, expanding production capacity, enhancing its protein optimization platform, and advancing global collaborations.

Keywords: protein technology, protein R&D, biomedical reagents, biomaterials, cell therapy, gene therapy, mRNA vaccines, molecular diagnostics, oncology, drug development, protein engineering, synthetic biology, proteomics, GMP manufacturing, life sciences, companion diagnostics, quality control reagents, CGT raw materials, AI in biotechnology, Cell-Free Protein Synthesis